AR041467A1 - Indol-3-carboxamidas como activadores de glucoquinasa (gk) - Google Patents
Indol-3-carboxamidas como activadores de glucoquinasa (gk)Info
- Publication number
- AR041467A1 AR041467A1 ARP030103589A ARP030103589A AR041467A1 AR 041467 A1 AR041467 A1 AR 041467A1 AR P030103589 A ARP030103589 A AR P030103589A AR P030103589 A ARP030103589 A AR P030103589A AR 041467 A1 AR041467 A1 AR 041467A1
- Authority
- AR
- Argentina
- Prior art keywords
- carbon atom
- ring
- heteroaromatic ring
- trifluoromethyl
- cyano
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Diabetes (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Se proporciona compuestos de glucoquinasa que son útiles para incrementar la secreción de insulina en el tratamiento de diabetes de tipo II. También se reivindica proceso de obtención y composición farmacéutica. Reivindicación 1: Un compuesto de la fórmula (1), en donde: R1 es halógeno, nitro, amino, ciano, metilo, trifluorometilo, hidroxilo, metoxilo, trifluorometoxilo, metiltio, metilsulfinilo, o metilsulfonilo; R2 es alquilo inferior C2-5 o -CH2-R4 en donde R4 es cicloalquilo C3-6; y R3 es un anillo heteroaromático de cinco o seis miembros mono sustituido o no sustituido conectado por un átomo de carbono del anillo al grupo amina mostrado, cuyo anillo heteroaromático de cinco o seis miembros contiene de 1 a 3 heteroátomos seleccionados de azufre, oxígeno o nitrógeno, con un heteroátomo siendo nitrógeno que está adyacente al átomo de carbono del anillo enlanzante; dicho anillo heteroaromático mono sustituido siendo monosustituido en una posición en un átomo de carbono del anillo otro que el adyacente a dicho átomo de carbono enlazante con un sustituyente seleccionado del grupo que consiste en metilo, trifluorometilo, cloro, bromo, nitro, ciano, o un resto de grupo de fórmula (2); en donde n es 0 ó 1; y R5 es hidrógeno o alquilo inferior; o una sal aceptable farmacéuticamente de la misma.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US41573702P | 2002-10-03 | 2002-10-03 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR041467A1 true AR041467A1 (es) | 2005-05-18 |
Family
ID=32069904
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP030103589A AR041467A1 (es) | 2002-10-03 | 2003-10-01 | Indol-3-carboxamidas como activadores de glucoquinasa (gk) |
Country Status (29)
| Country | Link |
|---|---|
| US (1) | US6881844B2 (es) |
| EP (1) | EP1549638B1 (es) |
| JP (1) | JP4390704B2 (es) |
| KR (1) | KR100646486B1 (es) |
| CN (1) | CN100348596C (es) |
| AR (1) | AR041467A1 (es) |
| AT (1) | ATE374768T1 (es) |
| AU (1) | AU2003270285B2 (es) |
| BR (1) | BR0315047A (es) |
| CA (1) | CA2499329C (es) |
| DE (1) | DE60316709T2 (es) |
| DK (1) | DK1549638T3 (es) |
| ES (1) | ES2293005T3 (es) |
| HK (1) | HK1083098A1 (es) |
| HR (1) | HRP20050287A2 (es) |
| MX (1) | MXPA05003391A (es) |
| MY (1) | MY136764A (es) |
| NO (1) | NO20051103L (es) |
| NZ (1) | NZ538466A (es) |
| PA (1) | PA8584001A1 (es) |
| PE (1) | PE20050090A1 (es) |
| PL (1) | PL375149A1 (es) |
| PT (1) | PT1549638E (es) |
| RU (1) | RU2309956C2 (es) |
| SI (1) | SI1549638T1 (es) |
| TW (1) | TW200413364A (es) |
| UY (1) | UY28005A1 (es) |
| WO (1) | WO2004031179A1 (es) |
| ZA (1) | ZA200502619B (es) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE0102299D0 (sv) | 2001-06-26 | 2001-06-26 | Astrazeneca Ab | Compounds |
| SE0102764D0 (sv) | 2001-08-17 | 2001-08-17 | Astrazeneca Ab | Compounds |
| EP1549626A1 (en) * | 2002-10-03 | 2005-07-06 | Novartis AG | Substituted (thiazol-2-yl) -amide or sulfonamide as glycokinase activators useful in the treatment of type 2 diabetes |
| GB0226930D0 (en) * | 2002-11-19 | 2002-12-24 | Astrazeneca Ab | Chemical compounds |
| GB0226931D0 (en) | 2002-11-19 | 2002-12-24 | Astrazeneca Ab | Chemical compounds |
| EP1532980A1 (en) * | 2003-11-24 | 2005-05-25 | Novo Nordisk A/S | N-heteroaryl indole carboxamides and analogues thereof, for use as glucokinase activators in the treatment of diabetes |
| CA2560689C (en) | 2004-04-02 | 2011-03-01 | Novartis Ag | Sulfonamide-thiazolpyridine derivatives as glucokinase activators useful in the treatment of type 2 diabetes |
| RU2006138426A (ru) | 2004-04-02 | 2008-05-10 | Новартис АГ (CH) | Производные тиазолопиридина, содержащие их фармацевтические композиции и способы лечения состояний, опосредованных глюкокиназой |
| US8957070B2 (en) | 2005-04-20 | 2015-02-17 | Takeda Pharmaceutical Company Limited | Glucokinase activator compounds, methods of activating glucokinase and methods of treating diabetes and obesity |
| US7622492B2 (en) | 2005-08-31 | 2009-11-24 | Hoffmann-La Roche Inc. | Pyrazolones as inhibitors of 11β-hydroxysteroid dehydrogenase |
| JP2007063225A (ja) | 2005-09-01 | 2007-03-15 | Takeda Chem Ind Ltd | イミダゾピリジン化合物 |
| NZ566877A (en) | 2005-09-29 | 2010-05-28 | Sanofi Aventis | Phenyl-1,2,4-oxadiazolone derivatives, processes for their preparation and their use as pharmaceuticals |
| GT200600428A (es) * | 2005-09-30 | 2007-05-21 | Compuestos organicos | |
| JP4990783B2 (ja) * | 2005-09-30 | 2012-08-01 | Ｍｓｄ株式会社 | ２−ヘテロアリール置換インドール誘導体 |
| GT200600429A (es) * | 2005-09-30 | 2007-04-30 | Compuestos organicos | |
| JP2009013065A (ja) * | 2005-10-14 | 2009-01-22 | Astellas Pharma Inc | 縮合へテロ環化合物 |
| JP2009515997A (ja) * | 2005-11-18 | 2009-04-16 | タケダ サン ディエゴ インコーポレイテッド | グルコキナーゼ活性剤 |
| US7351706B2 (en) * | 2006-01-05 | 2008-04-01 | Hoffmann-La Roche Inc. | Indol-3-yl-carbonyl-spiro-piperidine derivatives |
| JP5302012B2 (ja) | 2006-03-08 | 2013-10-02 | タケダ カリフォルニア インコーポレイテッド | グルコキナーゼ活性剤 |
| EP1849785A1 (en) * | 2006-04-28 | 2007-10-31 | Neuropharma, S.A. | N-(2-Thiazolyl)-amide derivatives as GSK-3 inhibitors |
| PE20110235A1 (es) | 2006-05-04 | 2011-04-14 | Boehringer Ingelheim Int | Combinaciones farmaceuticas que comprenden linagliptina y metmorfina |
| WO2007143434A2 (en) * | 2006-05-31 | 2007-12-13 | Takeda San Diego, Inc. | Indazole and isoindole derivatives as glucokinase activating agents |
| GEP20115241B (en) | 2006-10-19 | 2011-06-10 | Takeda Pharmaceutical | Indole compound |
| WO2008074694A1 (en) * | 2006-12-20 | 2008-06-26 | F. Hoffmann-La Roche Ag | Crystallization of glucokinase activators |
| US8163779B2 (en) | 2006-12-20 | 2012-04-24 | Takeda San Diego, Inc. | Glucokinase activators |
| US8173645B2 (en) | 2007-03-21 | 2012-05-08 | Takeda San Diego, Inc. | Glucokinase activators |
| WO2009023623A1 (en) * | 2007-08-10 | 2009-02-19 | H, Lundbeck A/S | Heteroaryl amide analogues |
| EP2294053B1 (en) | 2008-05-16 | 2016-01-06 | Takeda California, Inc. | Glucokinase activators |
| ES2528946T3 (es) | 2009-03-20 | 2015-02-13 | University Of Virginia Patent Foundation | Benzotiofeno-nitrotiazolida y otros antimicrobianos de amplio espectro |
| JP2011006366A (ja) | 2009-06-26 | 2011-01-13 | Sanwa Kagaku Kenkyusho Co Ltd | 新規チオフェンカルボキサミド誘導体及びその医薬用途 |
| WO2012040170A2 (en) | 2010-09-20 | 2012-03-29 | University Of Virginia Patent Foundation | Compositions and methods for treating tuberculosis |
| CN103044310B (zh) * | 2013-01-18 | 2015-02-04 | 贵阳医学院 | 二氢吲哚-3-乙酸衍生物、其制备方法以及在药物中的应用 |
| WO2023067628A1 (en) * | 2021-10-20 | 2023-04-27 | Council Of Scientific And Industrial Research An Indian Registered Body Incorporated Under The Regn. Of Soc. Act (Act Xxi Of 1860) | A method for the preparation of indole-3-carboxylic acid derivatives |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2740686B1 (fr) | 1995-11-03 | 1998-01-16 | Sanofi Sa | Formulation pharmaceutique lyophilisee stable |
| US6262096B1 (en) | 1997-11-12 | 2001-07-17 | Bristol-Myers Squibb Company | Aminothiazole inhibitors of cyclin dependent kinases |
| US6040321A (en) | 1997-11-12 | 2000-03-21 | Bristol-Myers Squibb Company | Aminothiazole inhibitors of cyclin dependent kinases |
| JP5278983B2 (ja) | 1999-11-17 | 2013-09-04 | 塩野義製薬株式会社 | アミド化合物の新規用途 |
| ATE316965T1 (de) | 2000-12-06 | 2006-02-15 | Hoffmann La Roche | Kondensierte heteroaromatische glucokinaseaktivatoren |
| US6433188B1 (en) | 2000-12-06 | 2002-08-13 | Wendy Lea Corbett | Fused heteroaromatic glucokinase activators |
| US6482951B2 (en) | 2000-12-13 | 2002-11-19 | Hoffmann-La Roche Inc. | Isoindolin-1-one glucokinase activators |
| CA2430978C (en) | 2000-12-28 | 2012-05-15 | Daiichi Pharmaceutical Co., Ltd. | Vla-4 inhibitors |
| UA77303C2 (en) * | 2002-06-14 | 2006-11-15 | Pfizer | Derivatives of thienopyridines substituted by benzocondensed heteroarylamide useful as therapeutic agents, pharmaceutical compositions and methods for their use |
-
2003
- 2003-09-26 BR BR0315047-0A patent/BR0315047A/pt not_active IP Right Cessation
- 2003-09-26 JP JP2004540731A patent/JP4390704B2/ja not_active Expired - Fee Related
- 2003-09-26 EP EP03750648A patent/EP1549638B1/en not_active Expired - Lifetime
- 2003-09-26 AU AU2003270285A patent/AU2003270285B2/en not_active Ceased
- 2003-09-26 ES ES03750648T patent/ES2293005T3/es not_active Expired - Lifetime
- 2003-09-26 PL PL03375149A patent/PL375149A1/xx not_active Application Discontinuation
- 2003-09-26 DK DK03750648T patent/DK1549638T3/da active
- 2003-09-26 SI SI200331008T patent/SI1549638T1/sl unknown
- 2003-09-26 RU RU2005113719/04A patent/RU2309956C2/ru not_active IP Right Cessation
- 2003-09-26 WO PCT/EP2003/010776 patent/WO2004031179A1/en active IP Right Grant
- 2003-09-26 PT PT03750648T patent/PT1549638E/pt unknown
- 2003-09-26 NZ NZ538466A patent/NZ538466A/en unknown
- 2003-09-26 KR KR1020057005669A patent/KR100646486B1/ko not_active IP Right Cessation
- 2003-09-26 CA CA002499329A patent/CA2499329C/en not_active Expired - Fee Related
- 2003-09-26 CN CNB038236796A patent/CN100348596C/zh not_active Expired - Fee Related
- 2003-09-26 MX MXPA05003391A patent/MXPA05003391A/es active IP Right Grant
- 2003-09-26 AT AT03750648T patent/ATE374768T1/de not_active IP Right Cessation
- 2003-09-26 DE DE60316709T patent/DE60316709T2/de not_active Expired - Lifetime
- 2003-09-30 PE PE2003000988A patent/PE20050090A1/es not_active Application Discontinuation
- 2003-09-30 PA PA20038584001A patent/PA8584001A1/es unknown
- 2003-09-30 US US10/674,481 patent/US6881844B2/en not_active Expired - Fee Related
- 2003-09-30 TW TW092127030A patent/TW200413364A/zh unknown
- 2003-10-01 MY MYPI20033742A patent/MY136764A/en unknown
- 2003-10-01 UY UY28005A patent/UY28005A1/es not_active Application Discontinuation
- 2003-10-01 AR ARP030103589A patent/AR041467A1/es unknown
-
2005
- 2005-03-01 NO NO20051103A patent/NO20051103L/no not_active Application Discontinuation
- 2005-03-24 HR HR20050287A patent/HRP20050287A2/xx not_active Application Discontinuation
-
2006
- 2006-01-19 ZA ZA200502619A patent/ZA200502619B/en unknown
- 2006-04-10 HK HK06104334A patent/HK1083098A1/xx not_active IP Right Cessation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR041467A1 (es) | Indol-3-carboxamidas como activadores de glucoquinasa (gk) | |
| AR031066A1 (es) | Un compuesto que comprende una amida, un proceso para su preparacion, composicion farmaceutica y el uso de dichos compuestos para la preparacion de medicamentos | |
| AR042602A1 (es) | Compuestos de 1,2,4-triazol | |
| UA94424C2 (en) | 1-heterocyclylsulfonyl, 2-aminomethyl, 5-(hetero-)aryl substituted 1-h-pyrrole derivatives as acid secretion inhibitors | |
| DE602006007012D1 (de) | Pyridinderivate als dipeptedyl-peptidase-hemmer | |
| UY28121A1 (es) | Activadores de glucoquinasa heteroaromaticos de seis miembros 5-sustituidos | |
| CO5700757A2 (es) | Derivados de (3-oxo-3,4-dihidro-quinoxalin-2-il-amino)-benzamida y compuesto relacionado, como inhibidores de glucogeno fosforilasa para el tratamiento de la diabetes y obesidad | |
| EA200600935A1 (ru) | Гетероциклические соединения бороновой кислоты | |
| BR0013041A (pt) | Composto heterociclico e composição farmacêutica para tratar e prevenir doenças mediadas por cgmp-pde, seu uso e método | |
| PE20020386A1 (es) | Derivados de tetrazolil-fenil acetamida como activadores de glucoquinasa | |
| NO20066015L (no) | Fuserte heterosykliske forbindelser | |
| AR036597A1 (es) | Derivados de 1h-imidazol que tienen actividad agonista de cb1, agonista parcial de cb1 o antagonista de cb1 | |
| AR053415A1 (es) | Inhibidores dipeptidil peptidasa iv, composiciones farmaceuticas que los contienen y procesos para la preparacion de los compuestos y de la composicion | |
| AR048362A1 (es) | Derivados de tetrahidronaftiridina y proceso para la preparacion de los mismos | |
| UY30897A1 (es) | Derivados de pentafluorotiobenzamidoacetonitrilo, composiciones conteniéndolos y aplicaciones | |
| DE602005023343D1 (de) | Pyrimidinderivate als gpcr-agonisten | |
| AR056574A1 (es) | Derivados de pirazol, composiciones que contienen dichos compuestos y procedimientos de uso | |
| CO5060482A1 (es) | Derivados terapeuticos de biarilo | |
| PE20090601A1 (es) | Derivados de piridin-il-oxi-piridinas como inhibidores de alk5 | |
| CO5590895A2 (es) | Derivados de sulfonamidas, su preparacion y su aplicacion como medicamentos | |
| AR061369A1 (es) | Derivados de pirimidina y composiciones farmaceuticas que los comprenden | |
| EP1783116A4 (en) | 2-PHENYLPYRIDINE DERIVATIVE | |
| AR053554A1 (es) | Derivados de pirimidina para el tratamiento de trastornos hiperproliferativos | |
| AR066962A1 (es) | Compuesto heterociclico fusionado | |
| AR053895A1 (es) | Aminopirimidinas como moduladores de quinasas |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |